sulfonylurea

(redirected from Sulphonylurea)
Also found in: Dictionary, Thesaurus, Wikipedia.

sulfonylurea

 [sul″fo-nil-u´re-ah]
any of a class of compounds that exert hypoglycemic activity by stimulating the islet tissue to secrete insulin; used to control hyperglycemia in patients with type 2 diabetes mellitus who cannot be treated solely by diet and exercise. The class includes the oral hypoglycemic agentsacetohexamide, chlorpropamide, glipizide, tolazamide, and tolbutamide.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

sulfonylurea

(sŭl′fə-nĭl-yo͝o-rē′ə)
n.
Any of a group of hypoglycemic drugs, such as glyburide, that act on the beta cells of the pancreas to increase the secretion of insulin and are used in the treatment of type 2 diabetes.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.
References in periodicals archive ?
In the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS), fewer people receiving canagliflozin (n=162) experienced hypoglycaemia compared to those receiving sulphonylurea (n=159) (adjusted odds ratio: 0.273 [95% CI: 0.104, 0.719]).
We describe the first homozygous ABCC8 mutation with hyperinsulinemic hypoglycaemia (HH) in the neonatal period and its evolution to complete insulin deficient, sulphonylurea responsive diabetes mellitus.
Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Nazim et al., "The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation," Diabetologia, vol.
Of these 70% had hypoglycaemia with sulphonylureas.
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Rifampicin, which is key among the cocktail of anti-TB drugs, through enzyme induction, accelerates the metabolism of sulphonylureas and biguanides, reducing their plasma levels and thereby leading to hyperglycemia [3, 41].
Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metfomin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
Among sulphonylurea, Glimepiride was more prescribed (23.5%), than Glibenclamide (17.5%) and Gliclazide (4%).
"Patients treated with metformin had a small but statistically signiY=cant improvement in survival compared with the non-diabetics, whereas those treated with sulphonylureas had a consistently reduced survival compared with nondiabetic patients.
Complexation of sulphonylurea with lighter transition metals has been studied in detail by Yoshinaga and Yamamotto [5, 6] and complexation of sulphonylurea and biguanidine by Iqbal et al.